1.1876

3.45% -0.0424

Neurosense Therapeutics Ltd (NRSN)

Overview News Price History Discussions Forecast

Neurosense Therapeutics Ltd stock is traded at $1.1876, with a volume of 236.89K. It is down -3.45% in the last 24 hours and up +14.19% over the past month. NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Previous Close:

$1.23

Open:

$1.24

24h Volume:

236.89K

Relative Volume:

0.40

Market Cap:

$35.27M

Revenue:

Net Income/Loss:

$-10.21M

P/E Ratio:

-2.0329

EPS:

-0.5842

Net Cash Flow:

1W Performance:

+1.50%

1M Performance:

+14.19%

6M Performance:

-30.14%

1Y Performance:

+10.99%

1-Day Range:

$1.15

$1.24

1-Week Range:

$1.07

$1.24

52-Week Range:

$0.81

$2.60

Neurosense Therapeutics Ltd Stock (NRSN) Company Profile

Name

Neurosense Therapeutics Ltd

Sector

Healthcare (1131)

Industry

Biotechnology (632)

Phone

Address

Employee

Twitter

Next Earnings Date

2025-11-26

Latest SEC Filings

NRSN's Discussions on Twitter

Compare NRSN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NRSN Neurosense Therapeutics Ltd	1.1876	36.53M	0	-10.21M	0	-0.5842
VRTX Vertex Pharmaceuticals Inc	457.26	117.50B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	722.83	76.06B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	464.56	62.53B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	916.31	56.75B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	205.04	44.10B	447.02M	-1.18B	-906.14M	-6.1812

Neurosense Therapeutics Ltd Stock (NRSN) Latest News

02:51 AM

Will NeuroSense Therapeutics Ltd. (H1Z) stock outperform value peersEarnings Summary Report & Daily Oversold Stock Bounce Ideas - Newser

02:51 AM

02:28 AM

How strong is NeuroSense Therapeutics Ltd. Equity Warrant stock balance sheetMarket Performance Report & Verified Short-Term Trading Plans - Newser

02:28 AM

Dec 04, 2025

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - Nasdaq

Dec 04, 2025

NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug - TipRanks

Dec 04, 2025

Neurosense Therapeutics LtdResuming Regulatory Advancement In Canada For Primec In Amyotrophic Lateral Sclerosis - TradingView

Dec 04, 2025

Is NeuroSense Therapeutics Ltd. stock overvalued by current metricsMarket Growth Review & Capital Protection Trading Alerts - Newser

Dec 04, 2025

How interest rate cuts could boost NeuroSense Therapeutics Ltd. Equity Warrant stockWeekly Trade Summary & AI Enhanced Trade Execution Alerts - Newser

Dec 04, 2025

Dec 02, 2025

What downside risks could hit NeuroSense Therapeutics Ltd. (H1Z) stockPortfolio Value Summary & Risk Managed Investment Signals - Newser

Dec 02, 2025

Dec 01, 2025

Aug EndMonth: How NeuroSense Therapeutics Ltd stock compares to growth peersWeekly Investment Report & Risk Managed Investment Strategies - BỘ NỘI VỤ

Dec 01, 2025

Nov 29, 2025

Is NeuroSense Therapeutics Ltd H1Z a good long term investmentMean Reversion Trades & High Return Capital Strategies - earlytimes.in

Nov 29, 2025

Nov 28, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) - Aktiellt

Nov 28, 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire) - Aktiellt

Nov 28, 2025

Nov 27, 2025

Hedge Fund Moves: How NeuroSense Therapeutics Ltd. stock compares to growth peers2025 Bull vs Bear & Proven Capital Preservation Methods - moha.gov.vn

Nov 27, 2025

Nov 25, 2025

NeuroSense Therapeutics (NASDAQ:NRSN) Given “Buy” Rating at D. Boral Capital - Defense World

Nov 25, 2025

NeuroSense Gains FDA Approval for Phase 3 ALS Trial - MSN

Nov 25, 2025

Prepare Yourself for Liftoff: NeuroSense Therapeutics Ltd (NRSN) - Setenews

Nov 25, 2025

Nov 24, 2025

D. Boral Capital Maintains NeuroSense Therapeutics (NRSN) Buy Recommendation - Nasdaq

Nov 24, 2025

NeuroSense receives FDA clearance to initiate pivotal phase 3 trial for PrimeC in ALS - marketscreener.com

Nov 24, 2025

NeuroSense Therapeutics (NRSN) Maintains 'Buy' Rating and $14 Ta - GuruFocus

Nov 24, 2025

NeuroSense Therapeutics Cleared by FDA to Initiate Phase 3 Trial for PrimeC to Treat ALS - marketscreener.com

Nov 24, 2025

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - Barchart.com

Nov 24, 2025

NeuroSense (Nasdaq: NRSN) to start pivotal Phase 3 PARAGON trial of PrimeC in ALS - Stock Titan

Nov 24, 2025

Nov 21, 2025